Partnering
Opportunities

At ViGeneron, we’re experts in developing new gene therapy solutions.
While we’re focused on gene therapy to cure ophthalmic diseases, our next-generation gene therapy technology platforms also offer opportunities for use in other diseases such as those affecting the central nervous system, liver, or cardiovascular system.

The vgAAV vector platform, based on novel engineered AAV capsids, enables a superior transduction of target cells and is designed to efficiently cross biological barriers. These attributes enable intravitreal, less invasive gene delivery but also allows vgAAV vectors to target a broad spectrum of cell types in the retina and potentially in other tissues, such as the central nervous system.

In addition, our REVeRT vector platform utilizes a unique mRNA trans-splicing technology to develop safe and effective AAV gene therapy targeting large genes (>5Kb). REVeRT achieves high reconstitution efficiencies at the mRNA and protein level and is broadly applicable for various disease areas.

We are actively looking to work with leading biopharmaceutical companies or academics that wish to exploit these opportunities.

If you are interested in our technologies, please contact us: partnering@vigeneron.com

Our Partnerships

Ludwig-Maximillians-Universität
LMU is recognized as one of Europe's premier academic and research institutions. The research group of Professor Martin Biel at the Department of Pharmacy attracts scholars and talented students from all over the world. Outstanding scientists work there to develop new techniques for advanced gene therapies.

 

WuXi Advanced Therapies
The Advanced Therapies business unit of WuXi AppTec is dedicated to accelerating and transforming development, manufacturing, and commercialization of cell, gene, and other advanced biopharmaceuticals.